Saturday 17 October 2026
Export HRMY’s income statement to Excel — free account
Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
38.20
0.07
−0.18%
Follow HRMY
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 7 | 4 | 5 | 7 | — | — | — | — |
P/E ratio |
13.61 | 13.44 | 14.25 | 17.31 | 71.07 | 0.00 | 0.00 | — | — |
Altman Z-Score |
5.23 | 5.29 | 5.02 | 8.46 | 6.51 | 0.96 | — | — | — |
P/S ratio |
2.48 | 2.74 | 3.15 | 7.16 | 8.03 | 5.83 | 0.00 | — | — |
P/FCF ratio |
6.99 | 10.96 | 10.23 | 30.05 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
7.17 | 5.98 | 4.76 | 4.57 | 2.23 | (1.18) | (21.50) | — | — |
Beneish M-Score |
(2.99) | (2.64) | (2.64) | (1.55) | (2.43) | 19.29 | — | — | — |
P/Operating CF |
17.05 | 25.91 | 23.88 | 117.47 | 65.36 | 92.73 | 59.79 | — | — |
P/B ratio |
2.47 | 2.97 | 3.92 | 7.78 | 13.15 | 9.59 | 0.00 | — | — |
Price to Tangible BV |
2.76 | 3.59 | 5.55 | 12.96 | 57.60 | 0.00 | 0.00 | — | — |
EV/Sales |
1.77 | 2.34 | 2.87 | 6.86 | 7.89 | 5.62 | 0.00 | — | — |
EV/EBITDA |
6.61 | 7.82 | 7.74 | 20.73 | 22.20 | 30.28 | 0.00 | — | — |
EV/Operating CF |
4.42 | 7.59 | 7.62 | 20.78 | 24.46 | (300.60) | (8.62) | — | — |
EV/FCF |
5.00 | 9.34 | 9.33 | 28.79 | (1,384.74) | (296.82) | (8.62) | — | — |
Quick Ratio |
3.46 | 3.14 | 2.61 | 4.79 | 5.01 | 1.86 | 1.44 | 11.55 | — |
Current Ratio |
3.60 | 3.31 | 2.75 | 5.07 | 5.29 | 1.95 | 1.58 | 11.99 | — |
Net Debt/EBITDA |
(2.63) | (1.35) | (0.74) | (0.91) | (0.39) | (1.16) | (0.52) | (5.83) | — |
Debt/Assets |
12.87% | 17.94% | 23.85% | 28.44% | 44.29% | 45.48% | 91.79% | 363.12% | 0.00% |
Debt/Equity |
0.19 | 0.27 | 0.41 | 0.48 | 1.03 | 2.00 | (8.45) | (1.34) | — |
Asset Turnover |
0.76 | 0.79 | 0.78 | 0.79 | 0.71 | 0.60 | 0.06 | 0.00 | — |
Operating CF/Net income |
2.19 | 1.51 | 1.70 | 0.80 | 2.85 | 0.05 | 0.40 | 0.55 | — |
Capex/Depreciation |
(0.01) | (0.05) | (0.01) | (1.63) | (4.76) | (0.16) | (33.44) | 0.00 | — |
Interest Coverage |
14.23 | 10.91 | 8.08 | 6.39 | 3.62 | 0.60 | (24.02) | (53.78) | — |
| 20.75% | 25.84% | 29.63% | 61.58% | 24.39% | 39.21% | 56.26% | 21.06% | — | |
| 13.98% | 16.07% | 17.35% | 32.78% | 8.04% | (23.92%) | (191.04%) | (156.99%) | — | |
ROIC |
50.40% | 32.13% | 39.08% | 27.68% | 37.94% | 16.91% | (147.31%) | 0.00% | — |
Return on Tangible Assets |
24.23% | 35.89% | 44.79% | 56.36% | 14.95% | (49.38%) | (1,447.30%) | (86.49%) | — |
Average Days of Receivables |
40.68 | 42.40 | 46.50 | 45.63 | 41.64 | 50.67 | 259.06 | — | — |
Research and Development Expense of Revenue |
21.83% | 20.40% | 13.07% | 16.19% | 9.94% | 12.17% | 1,160.88% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
31.33% | 30.96% | 33.11% | 37.30% | 43.23% | 59.83% | 1,346.57% | 0.00% | — |
Intangible Assets out of Total Assets |
0.07 | 0.11 | 0.17 | 0.24 | 0.33 | 0.38 | 0.68 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
5.17% | 5.96% | 5.45% | 5.98% | 5.13% | 2.94% | 165.29% | — | — |
Graham Net Nets |
0.24 | 0.12 | 0.06 | 0.04 | 0.02 | (0.07) | 0.34 | — | — |
Graham Number |
30.60 | 25.83 | 19.54 | 21.65 | 6.62 | 0.00 | 0.00 | — | — |
Earnings Yield |
7.35% | 7.44% | 7.02% | 5.78% | 1.41% | (14.11%) | (25.70%) | — | — |
Free Cash Flow Yield |
14.31% | 9.13% | 9.78% | 3.33% | (0.07%) | (0.32%) | (33.68%) | — | — |
Revenue per Share |
15.11 | 12.56 | 9.79 | 7.40 | 5.31 | 6.20 | 0.77 | 0.00 | — |
Operating CF per Share |
6.06 | 3.86 | 3.69 | 2.44 | 1.71 | (0.12) | (9.70) | (0.61) | — |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.68) | (1.74) | (0.08) | (16.35) | 0.00 | — |
Free Cash Flow per Share |
6.05 | 3.84 | 3.68 | 1.76 | (0.03) | (0.19) | (26.05) | (0.61) | — |
Cash per Share |
13.49 | 8.21 | 5.94 | 5.46 | 4.07 | 8.87 | 3.14 | 1.31 | — |
Shareholders Equity per Share |
15.14 | 11.59 | 7.85 | 6.81 | 3.24 | 3.77 | (1.49) | (3.81) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
15.14 | 11.59 | 7.85 | 6.81 | 3.24 | 3.77 | (1.49) | (3.81) | — |
Free Cash Flow |
347.89 | 218.67 | 219.08 | 104.29 | (1.74) | (4.99) | (202.58) | (38.80) | — |
Working Capital |
654.88 | 404.17 | 287.29 | 321.40 | 230.66 | 128.35 | 11.61 | 79.45 | — |
Capital Expenditures |
(0.31) | (1.15) | (0.31) | (40.17) | (100.30) | (2.00) | (127.15) | (1.34) | — |
Net Current Asset Value |
505.60 | 239.21 | 106.61 | 129.25 | 37.50 | (67.00) | (86.79) | (245.27) | — |
EV/EBIT |
7.39 | 8.75 | 8.70 | 24.98 | 27.54 | 52.82 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.09 | 0.33 | 0.01 | 21.21 | — | — |
Price to Operating Income |
10.32 | 10.26 | 9.54 | 26.07 | 28.03 | 54.85 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 17.94 | 64.47 | 42.96 | 25.70 | 13.49 | 2.86 | 0.12 | — |
Cash ROIC |
19.23% | 16.75% | 21.60% | 11.37% | (0.28%) | (0.96%) | (182.81%) | (23.51%) | — |
Accounts Receivable Turnover |
9.66 | 9.09 | 9.03 | 9.78 | 10.71 | 12.09 | 0.45 | — | — |
Accounts Payable Turnover |
12.62 | 9.96 | 11.27 | 34.88 | 31.22 | 6.22 | 0.40 | 0.05 | — |
Inventory Turnover |
31.60 | 24.97 | 25.10 | 19.13 | 13.45 | 11.30 | 0.64 | 0.00 | — |
Average Days of Payables |
32.56 | 31.99 | 53.38 | 16.55 | 6.58 | 33.63 | 1,472.04 | 2,900.16 | — |
Days of Inventory on Hand |
9.86 | 16.75 | 16.15 | 18.79 | 29.14 | 50.31 | 251.82 | 0.00 | — |
Average Receivables |
89.91 | 78.59 | 64.44 | 44.79 | 28.51 | 13.22 | 13.22 | — | — |
Average Payables |
15.72 | 15.74 | 10.76 | 2.39 | 1.78 | 4.46 | 3.91 | 3.91 | — |
Average Inventory |
6.28 | 6.28 | 4.83 | 4.36 | 4.13 | 2.46 | 2.46 | — | — |
Average Assets |
1,135.42 | 905.32 | 742.66 | 553.66 | 430.26 | 266.89 | 97.99 | 44.64 | — |
Average Common Equity |
764.69 | 563.07 | 434.92 | 294.67 | 141.84 | (162.84) | (332.77) | (332.77) | — |
Columns are period end dates